139 related articles for article (PubMed ID: 23948603)
1. Serum regulation of Id1 expression by a BMP pathway and BMP responsive element.
Lewis TC; Prywes R
Biochim Biophys Acta; 2013 Oct; 1829(10):1147-59. PubMed ID: 23948603
[TBL] [Abstract][Full Text] [Related]
2. Direct response elements of BMP within the PV.1A promoter are essential for its transcriptional regulation during early Xenopus development.
Lee HS; Lee SY; Lee H; Hwang YS; Cha SW; Park S; Lee JY; Park JB; Kim S; Park MJ; Kim J
PLoS One; 2011; 6(8):e22621. PubMed ID: 21857938
[TBL] [Abstract][Full Text] [Related]
3. BMP-2 decreases Mash1 stability by increasing Id1 expression.
Viñals F; Reiriz J; Ambrosio S; Bartrons R; Rosa JL; Ventura F
EMBO J; 2004 Sep; 23(17):3527-37. PubMed ID: 15318167
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression.
Yuen HF; McCrudden CM; Grills C; Zhang SD; Huang YH; Chan KK; Chan YP; Wong ML; Law S; Srivastava G; Fennell DA; Dickson G; El-Tanani M; Chan KW
Cancer Sci; 2012 Jun; 103(6):1145-54. PubMed ID: 22364398
[TBL] [Abstract][Full Text] [Related]
5. Optimal effector functions in human natural killer cells rely upon autocrine bone morphogenetic protein signaling.
Robson NC; Hidalgo L; Mc Alpine T; Wei H; Martínez VG; Entrena A; Melen GJ; MacDonald AS; Phythian-Adams A; Sacedón R; Maraskovsky E; Cebon J; Ramírez M; Vicente A; Varas A
Cancer Res; 2014 Sep; 74(18):5019-5031. PubMed ID: 25038228
[TBL] [Abstract][Full Text] [Related]
6. Conserved temporal ordering of promoter activation implicates common mechanisms governing the immediate early response across cell types and stimuli.
Vacca A; Itoh M; Kawaji H; Arner E; Lassmann T; Daub CO; Carninci P; Forrest ARR; Hayashizaki Y; ; Aitken S; Semple CA
Open Biol; 2018 Aug; 8(8):. PubMed ID: 30089658
[TBL] [Abstract][Full Text] [Related]
7. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer.
Jonk LJ; Itoh S; Heldin CH; ten Dijke P; Kruijer W
J Biol Chem; 1998 Aug; 273(33):21145-52. PubMed ID: 9694870
[TBL] [Abstract][Full Text] [Related]
8. Id proteins: small molecules, mighty regulators.
Ling F; Kang B; Sun XH
Curr Top Dev Biol; 2014; 110():189-216. PubMed ID: 25248477
[TBL] [Abstract][Full Text] [Related]
9. Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation.
Cao Y; Wang C; Zhang X; Xing G; Lu K; Gu Y; He F; Zhang L
Sci Rep; 2014 May; 4():4965. PubMed ID: 24828823
[TBL] [Abstract][Full Text] [Related]
10. Targeting BMP9-promoted human osteosarcoma growth by inactivation of notch signaling.
Li R; Zhang W; Cui J; Shui W; Yin L; Wang Y; Zhang H; Wang N; Wu N; Nan G; Chen X; Wen S; Deng F; Zhang H; Zhou G; Liao Z; Zhang J; Zhang Q; Yan Z; Liu W; Zhang Z; Ye J; Deng Y; Luu HH; Haydon RC; He TC; Deng ZL
Curr Cancer Drug Targets; 2014; 14(3):274-85. PubMed ID: 24605944
[TBL] [Abstract][Full Text] [Related]
11. Small molecule antagonist of the bone morphogenetic protein type I receptors suppresses growth and expression of Id1 and Id3 in lung cancer cells expressing Oct4 or nestin.
Langenfeld E; Deen M; Zachariah E; Langenfeld J
Mol Cancer; 2013 Oct; 12(1):129. PubMed ID: 24160469
[TBL] [Abstract][Full Text] [Related]
12. Control of neuronal excitation-inhibition balance by BMP-SMAD1 signalling.
Okur Z; Schlauri N; Bitsikas V; Panopoulou M; Ortiz R; Schwaiger M; Karmakar K; Schreiner D; Scheiffele P
Nature; 2024 May; 629(8011):402-409. PubMed ID: 38632412
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin small-molecule inhibitors promote osteogenesis by activating canonical Wnt and BMP pathways.
Sangadala S; Kim CH; Fernandes LM; Makkar P; Beck GR; Boden SD; Drissi H; Presciutti SM
Elife; 2023 Aug; 12():. PubMed ID: 37560905
[TBL] [Abstract][Full Text] [Related]
14. TGF-Beta Induces Activin A Production in Dermal Fibroblasts Derived from Patients with Fibrodysplasia Ossificans Progressiva.
de Ruiter RD; Wisse LE; Schoenmaker T; Yaqub M; Sánchez-Duffhues G; Eekhoff EMW; Micha D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768622
[TBL] [Abstract][Full Text] [Related]
15. ActivinA Induced SMAD1/5 Signaling in an iPSC Derived EC Model of Fibrodysplasia Ossificans Progressiva (FOP) Can Be Rescued by the Drug Candidate Saracatinib.
Hildebrandt S; Kampfrath B; Fischer K; Hildebrand L; Haupt J; Stachelscheid H; Knaus P
Stem Cell Rev Rep; 2021 Jun; 17(3):1039-1052. PubMed ID: 33410098
[TBL] [Abstract][Full Text] [Related]
16. Clinical Aspects and Current Therapeutic Approaches for FOP.
Kitoh H
Biomedicines; 2020 Sep; 8(9):. PubMed ID: 32887348
[TBL] [Abstract][Full Text] [Related]
17. Systems biology approach to exploring the effect of cyclic stretching on cardiac cell physiology.
Chen CC; Wong TY; Chin TY; Lee WH; Kuo CY; Hsu YC
Aging (Albany NY); 2020 Aug; 12(16):16035-16045. PubMed ID: 32759460
[TBL] [Abstract][Full Text] [Related]
18. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
19. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal.
Toofan P; Busch C; Morrison H; O'Brien S; Jørgensen H; Copland M; Wheadon H
Cell Death Dis; 2018 Sep; 9(9):927. PubMed ID: 30206237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
